Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors
Tóm tắt
Inefficient vascularization hinders the optimal transport of cell nutrients, oxygen, and drugs to cancer cells in solid tumors. Gradients of these substances maintain a heterogeneous cell-scale microenvironment through which drugs and their carriers must travel, significantly limiting optimal drug exposure. In this study, we integrate intravital microscopy with a mathematical model of cancer to evaluate the behavior of nanoparticle-based drug delivery systems designed to circumvent biophysical barriers. We simulate the effect of doxorubicin delivered via porous 1000 x 400 nm plateloid silicon particles to a solid tumor characterized by a realistic vasculature, and vary the parameters to determine how much drug per particle and how many particles need to be released within the vasculature in order to achieve remission of the tumor. We envision that this work will contribute to the development of quantitative measures of nanoparticle design and drug loading in order to optimize cancer treatment via nanotherapeutics.
Từ khóa
Tài liệu tham khảo
2010, Frontiers in cancer nanomedicine: directing mass transport through biological barriers, Trends Biotechnol, 28, 181, 10.1016/j.tibtech.2009.12.007
1999, Transport of Molecules, Particles, and Cells in Solid Tumors, Annual Review of Biomedical Engineering, 1, 241, 10.1146/annurev.bioeng.1.1.241
2010, Understanding and overcoming major barriers in cancer nanomedicine, Nanomedicine (Lond), 5, 523, 10.2217/nnm.10.23
2004, Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles, Biomed Microdevices, 6, 297, 10.1023/B:BMMD.0000048562.29657.64
2009, Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation, J Math Biol, 58, 485, 10.1007/s00285-008-0214-y
2009, Prediction of drug response in breast cancer using integrative experimental/computational modeling, Cancer Res, 69, 4484, 10.1158/0008-5472.CAN-08-3740
2010, Dissecting cancer through mathematics: from the cell to the animal model, Nature reviews, 10, 221, 10.1038/nrc2808
2010, Nonlinear modelling of cancer: bridging the gap between cells and tumours, Nonlinearity, 23, R1, 10.1088/0951-7715/23/1/R01
2007, Towards a multiscale model of colorectal cancer, World J Gastroenterol, 13, 1399, 10.3748/wjg.v13.i9.1399
2008, Multiphase Models of Tumour Growth: Selected Topics in Cancer Modeling, 1
2007, The evolution of mathematical modeling of glioma proliferation and invasion, J Neuropathol Exp Neurol, 66, 1, 10.1097/nen.0b013e31802d9000
2009, In silico cancer modeling: is it ready for prime time?, Nat Clin Pract Oncol, 6, 34, 10.1038/ncponc1237
2009, On the role of cell signaling models in cancer research, Cancer Res, 69, 400, 10.1158/0008-5472.CAN-08-4422
1998, Continuous and discrete mathematical models of tumor-induced angiogenesis, Bull Math Biol, 60, 857, 10.1006/bulm.1998.0042
2002, Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies, Bull Math Biol, 64, 673, 10.1006/bulm.2002.0293
2006, Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies, J Theor Biol, 241, 564, 10.1016/j.jtbi.2005.12.022
2006, Mathematical modelling of the influence of blood rheological properties upon adaptive tumour-induced angiogenesis, Math Comput Model, 44, 96, 10.1016/j.mcm.2004.07.021
2009, Angiogenesis and vascular remodelling in normal and cancerous tissues, J Math Biol, 58, 689, 10.1007/s00285-008-0213-z
2009, Multiscale modelling and nonlinear simulation of vascular tumour growth, J Math Biol, 58, 765, 10.1007/s00285-008-0216-9
2003, Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model, J Theor Biol, 220, 201, 10.1006/jtbi.2003.3156
2006, Modelling the response of spatially structured tumours to chemotherapy: drug kinetics, Math Comput Model, 43, 820, 10.1016/j.mcm.2005.09.026
2007, A mathematical model of breast cancer development, local treatment and recurrence, J Theor Biol, 246, 245, 10.1016/j.jtbi.2006.12.010
2005, Morphologic instability and cancer invasion, Clin Cancer Res, 11, 6772, 10.1158/1078-0432.CCR-05-0852
2006, An integrated computational/experimental model of tumor invasion, Cancer Res, 66, 1597, 10.1158/0008-5472.CAN-05-3166
2007, Computer simulation of glioma growth and morphology, Neuroimage, 37 Suppl 1, S59, 10.1016/j.neuroimage.2007.03.008
2010, Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis, J Theor Biol, 264, 1254, 10.1016/j.jtbi.2010.02.036
2006, Mathematical modeling of cancer progression and response to chemotherapy, Expert Rev Anticancer Ther, 6, 1361, 10.1586/14737140.6.10.1361
2006, Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment, Cell, 127, 905, 10.1016/j.cell.2006.09.042
2007, Nonlinear simulation of the effect of microenvironment on tumor growth, J Theor Biol, 245, 677, 10.1016/j.jtbi.2006.12.004
2005, Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method, Bull Math Biol, 67, 211, 10.1016/j.bulm.2004.08.001
The effect of interstitial pressure on tumor growth and transport of therapeutic agents: coupling with the blood and lymphatic vascular systems
2011, Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution
2010, Size and shape effects in the biodistribution of intravascularly injected particles, J Control Release, 141, 320, 10.1016/j.jconrel.2009.10.014
2008, Multistage mesoporous silicon-based nanocarriers: biocompatibility and controlled degradation in physiological fluids, 35th Annual Meeting & Exposition of the Controlled Release Society
2010, Sustained small interfering RNA delivery by mesoporous silicon particles, Cancer Res, 70, 3687, 10.1158/0008-5472.CAN-09-3931
2010, Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line, ACS Nano, 4, 4539, 10.1021/nn100690m
2009, Biodegradable luminescent porous silicon nanoparticles for in vivo applications, Nat Mater, 8, 331, 10.1038/nmat2398
2010, Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation, Journal of Biomedical Materials Research Part A, 94A, 1236, 10.1002/jbm.a.32807
1992, Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH, Journal of Cellular Physiology, 151, 386, 10.1002/jcp.1041510220
1994, Pharmacokinetic factors influencing risk assessment: saturation of biochemical processes and cofactor depletion, Environ Health Perspect, 102 Suppl 11, 13, 10.1289/ehp.94102s1113
1988, Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance, British journal of cancer, 58, 335, 10.1038/bjc.1988.214
2010, Tailored porous silicon microparticles: fabrication and properties, Chemphyschem, 11, 1029, 10.1002/cphc.200900914
2009, Intravascular delivery of particulate systems: does geometry really matter?, Pharm Res, 26, 235, 10.1007/s11095-008-9697-x
1999, Doxorubicin gradients in human breast cancer, Clin Cancer Res, 5, 1703
2005, The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors, Clin Cancer Res, 11, 8782, 10.1158/1078-0432.CCR-05-1664
2010, Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles, Small, 6, 2691, 10.1002/smll.201000727